This is simply because Ozempic drug trials focused on how it impacted blood sugar (like metformin does), while Wegovy drug trials focused on how it impacted weight
A joint UK-Denmark study, reported in Diabetes, Obesity & Metabolism, examined the effects of 12 weeks of treatment with once weekly subcutaneous semaglutide (doseescalated to 1.0mg) on appetite, energy intake, control of eating, food preference and body weight in 30 subjects with obesity
In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 semaglutide, tirzepatide, or injectable liraglutide without insulin in 2022
[DOI] [PubMed] [Google Scholar] 185.Hunt A., Harrington D., Robinson S
At PRIME Medicine, patients receive individualized care designed to support long-term metabolic health and sustainable weight management